ATE515506T1 - Verfahren zur synthese von 2- aminothiazolverbindungen als kinaseinhibitoren - Google Patents

Verfahren zur synthese von 2- aminothiazolverbindungen als kinaseinhibitoren

Info

Publication number
ATE515506T1
ATE515506T1 AT08708929T AT08708929T ATE515506T1 AT E515506 T1 ATE515506 T1 AT E515506T1 AT 08708929 T AT08708929 T AT 08708929T AT 08708929 T AT08708929 T AT 08708929T AT E515506 T1 ATE515506 T1 AT E515506T1
Authority
AT
Austria
Prior art keywords
synthesis
kinase inhibitors
aminothiazole compounds
aminothiazole
compounds
Prior art date
Application number
AT08708929T
Other languages
English (en)
Inventor
Alain Moussy
Philippe Reginault
Francois Bellamy
Anne Lermet
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Application granted granted Critical
Publication of ATE515506T1 publication Critical patent/ATE515506T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT08708929T 2007-02-13 2008-02-13 Verfahren zur synthese von 2- aminothiazolverbindungen als kinaseinhibitoren ATE515506T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88958707P 2007-02-13 2007-02-13
PCT/EP2008/051704 WO2008098949A2 (en) 2007-02-13 2008-02-13 Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE515506T1 true ATE515506T1 (de) 2011-07-15

Family

ID=39332208

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08708929T ATE515506T1 (de) 2007-02-13 2008-02-13 Verfahren zur synthese von 2- aminothiazolverbindungen als kinaseinhibitoren

Country Status (23)

Country Link
US (3) US8153792B2 (de)
EP (2) EP2366703B1 (de)
JP (2) JP5568312B2 (de)
KR (1) KR20090110851A (de)
CN (2) CN103342701B (de)
AR (1) AR065337A1 (de)
AT (1) ATE515506T1 (de)
AU (1) AU2008214679A1 (de)
BR (1) BRPI0807626B1 (de)
CA (2) CA2970628C (de)
ES (2) ES2369617T3 (de)
HR (2) HRP20110709T1 (de)
IL (1) IL200320A0 (de)
MA (1) MA31180B1 (de)
MX (1) MX2009008665A (de)
NZ (1) NZ578944A (de)
PL (2) PL2366703T3 (de)
RU (2) RU2456285C2 (de)
SI (2) SI2366703T1 (de)
TN (1) TN2009000342A1 (de)
TW (1) TWI406862B (de)
WO (1) WO2008098949A2 (de)
ZA (1) ZA200905981B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
DE60316810T2 (de) 2002-08-02 2008-07-17 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren
TW201202232A (en) 2010-01-28 2012-01-16 Ab Science Treatment of GIST with masitinib
TW201130830A (en) 2010-02-01 2011-09-16 Ab Science Combined treatment of pancreatic cancer with gemcitabine and masitinib
AR080380A1 (es) 2010-03-09 2012-04-04 Ab Science Tratamiento de la demencia tipo alzheimer con masitinib
US8906357B2 (en) 2010-04-20 2014-12-09 Ab Science Treatment of multiple sclerosis with masitinib
TW201204719A (en) 2010-06-02 2012-02-01 Ab Science Treatment of rheumatoid arthritis with masitinib
US20140147415A1 (en) 2010-11-05 2014-05-29 Ab Science Treatment of mastocytosis with masitinib
US10045978B2 (en) 2010-11-05 2018-08-14 Ab Science Treatment of mastocytosis with masitinib
WO2012104402A1 (en) * 2011-02-04 2012-08-09 Ab Science Treatment of severe persitent asthma with masitinib
US20140051662A1 (en) 2011-04-08 2014-02-20 Ab Science Treatment of multiple myeloma with masitinib
KR102149483B1 (ko) 2012-10-04 2020-08-28 에이비 사이언스 예측변수 인자들을 이용하여 동정된 환자 부분 모집단에서 암 치료를 위한 마시티닙의 용도
TW201605449A (zh) 2013-12-02 2016-02-16 Ａｂ化學公司 馬賽替尼治療結腸直腸癌的用途
EP2886543A1 (de) 2013-12-18 2015-06-24 Sandoz Ag Kristalline Form von Masitinib
US20170196853A1 (en) 2014-06-02 2017-07-13 Ab Science Use of an inhibitor of kinase activity, particularly masitinib, for treatment of prostate cancer
CN105585556A (zh) * 2014-11-13 2016-05-18 连云港杰瑞药业有限公司 一种伊马替尼的合成方法
CN106794179A (zh) * 2015-07-29 2017-05-31 苏州晶云药物科技有限公司 马赛替尼甲磺酸盐的新晶型及其制备方法
CA3000894A1 (en) 2015-10-05 2017-04-13 Ab Science Treatment of severe systemic mastocytosis with masitinib
BR112018069515A2 (pt) 2016-03-25 2019-04-16 Ab Science uso de masitinibe para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica
EP3601278B1 (de) 2017-03-31 2022-10-26 Sandoz AG Kristalline form von masitinib
US10696638B2 (en) 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
EP4061371B1 (de) 2019-11-22 2025-02-19 AB Science Masitinib zur behandlung von sichelzellanämie
EP3831384A1 (de) 2019-12-02 2021-06-09 AB Science Verwendung von masitinib zur behandlung von eosinophilem asthma
KR20220143020A (ko) 2020-02-20 2022-10-24 에이비 사이언스 다발 경화증 환자 하위집단의 치료를 위한 마시티닙
JP2023521403A (ja) 2020-04-10 2023-05-24 エービー サイエンス コロナウイルス病２０１９（ｃｏｖｉｄ－１９）の治療のためのマシチニブの使用
CN116963736A (zh) 2020-12-16 2023-10-27 Ab科学有限公司 马赛替尼用于治疗阿尔茨海默病
US20230321081A1 (en) 2021-05-17 2023-10-12 Ab Science Masitinib for the treatment of castrate-resistant prostate cancer
CN115850258B (zh) * 2022-12-27 2024-09-24 东北林业大学 一种马赛替尼的合成方法
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299087A (en) * 1961-04-24 1967-01-17 Geigy Chem Corp Nu, nu'-bis-(thiazolyl)-phenylenediamines
AR037061A1 (es) * 1997-05-22 2004-10-20 Searle & Co Compuesto derivado de pirazol sustituido, procesos para preparar dicho compuesto, composicion farmaceutica que lo contiene y su uso en la preparacion de medicamentos
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
UA66810C2 (uk) * 1997-10-27 2004-06-15 Агорон Фармацевтикалз Інк. Похідні 4-амінотіазолу та композиції на їх основі як інгібітори циклінозалежних кіназ
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
BR0013899A (pt) * 1999-09-10 2003-07-08 Merck & Co Inc Composto, composição farmacêutica, processos de tratamento ou prevenção de câncer, de uma doença em que a angiogênese esteja implicada, da vascularização retinal, da retinopatia diabética, da degeneração macular relacionada a idade, de doenças inflamatórias, de uma doença ou condições dependentes da tirosina quinase, de patologias associadas com ossos, e, processos para produzir uma composição farmacêutica, e de reduzir ou prevenir dano tecidual em seguida a um evento isquêmico cerebral
CA2452366A1 (en) 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
EP1471907B1 (de) 2001-06-29 2008-07-16 AB Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
PT1401416E (pt) 2001-06-29 2007-02-28 Ab Science Utilização de inibidores de c-kit para tratar doenças inflamatórias intestinais (dii)
US7700610B2 (en) 2001-06-29 2010-04-20 Ab Science Use of tyrosine kinase inhibitors for treating allergic diseases
EP1401414A2 (de) 2001-06-29 2004-03-31 AB Science Die verwendung von tyrosinkinasehemmer zur behandlung von multiple sclerosis
CA2452169A1 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
US20030091974A1 (en) 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
CA2452390A1 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating bone loss
US20050054617A1 (en) 2001-06-29 2005-03-10 Alain Moussy Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
EP1434991B1 (de) 2001-06-29 2007-10-17 AB Science C-kit inhibitoren
JP2005511596A (ja) 2001-09-20 2005-04-28 アブ サイエンス ヒトの皮膚を白くし、且つメラノサイト機能不全関連疾病を治療するためのチロシンキナーゼ阻害剤の使用方法
JP2005507916A (ja) 2001-09-20 2005-03-24 アブ サイエンス 細菌感染症を治療するための、強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤の使用方法
WO2003035050A2 (en) 2001-09-20 2003-05-01 Ab Science Use of tyrosine kinase inhibitors for promoting hair growth
CA2477111A1 (en) 2002-02-27 2003-09-04 Ab Science Use of tyrosine kinase inhibitors for treating cns disorders
DE60323613D1 (de) 2002-02-27 2008-10-30 Ab Science Verwendung von tyrosinkinase-hemmern zur behandlung von erkrankungen im zusammenhang mit substanzgebrauch
JP2005533039A (ja) * 2002-05-29 2005-11-04 アムゲン インコーポレイテッド 細胞増殖関連疾患治療用２−オキソ−１，３，４−トリヒドロキナゾリニル誘導体
DE60316810T2 (de) * 2002-08-02 2008-07-17 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren
SE0202462D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
AU2004212490B2 (en) * 2003-02-10 2008-05-15 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CA2517308A1 (en) 2003-02-27 2004-09-10 Ab Science Tailored treatment suitable for different forms of mastocytosis
FR2854158B1 (fr) * 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
WO2005011597A2 (en) * 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2535242A1 (en) 2003-08-15 2005-02-24 Ab Science Use of c-kit inhibitors for treating type ii diabetes
US7363881B2 (en) 2003-11-06 2008-04-29 Nova-Tech Engineering, Inc. Beak treatment with tongue protection
JPWO2005063709A1 (ja) * 2003-12-25 2007-07-19 日本新薬株式会社 アミド誘導体及び医薬
US7650848B2 (en) * 2004-02-17 2010-01-26 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
TW200702876A (en) * 2005-07-04 2007-01-16 Avermedia Tech Inc Projector device capable of sychronously encoding audio and video to become AV sychronous paly file

Also Published As

Publication number Publication date
ZA200905981B (en) 2010-11-24
CA2677586A1 (en) 2008-08-21
RU2491286C1 (ru) 2013-08-27
RU2456285C2 (ru) 2012-07-20
JP5784073B2 (ja) 2015-09-24
EP2118099A2 (de) 2009-11-18
JP2010518141A (ja) 2010-05-27
EP2366703A1 (de) 2011-09-21
HRP20110709T1 (hr) 2011-11-30
AU2008214679A1 (en) 2008-08-21
TWI406862B (zh) 2013-09-01
MA31180B1 (fr) 2010-02-01
US20100121063A1 (en) 2010-05-13
US20120196871A1 (en) 2012-08-02
RU2009132186A (ru) 2011-03-20
US8940894B2 (en) 2015-01-27
MX2009008665A (es) 2009-08-21
JP2013177437A (ja) 2013-09-09
AR065337A1 (es) 2009-06-03
ES2522169T3 (es) 2014-11-13
EP2118099B1 (de) 2011-07-06
TN2009000342A1 (en) 2010-12-31
CN101657446A (zh) 2010-02-24
TW200848419A (en) 2008-12-16
US8153792B2 (en) 2012-04-10
NZ578944A (en) 2011-03-31
CN103342701A (zh) 2013-10-09
CA2677586C (en) 2017-07-25
PL2118099T3 (pl) 2011-12-30
CA2970628C (en) 2019-08-27
CA2970628A1 (en) 2008-08-21
IL200320A0 (en) 2010-04-29
CN103342701B (zh) 2016-09-21
WO2008098949A3 (en) 2008-10-02
HRP20140986T1 (hr) 2014-11-21
ES2369617T3 (es) 2011-12-02
US20130289045A1 (en) 2013-10-31
BRPI0807626A2 (pt) 2014-11-25
BRPI0807626B1 (pt) 2022-03-03
CN101657446B (zh) 2013-05-15
EP2366703B1 (de) 2014-07-30
SI2366703T1 (sl) 2014-10-30
PL2366703T3 (pl) 2015-02-27
US8492545B2 (en) 2013-07-23
JP5568312B2 (ja) 2014-08-06
WO2008098949A2 (en) 2008-08-21
KR20090110851A (ko) 2009-10-22
SI2118099T1 (sl) 2011-11-30

Similar Documents

Publication Publication Date Title
ATE538111T1 (de) Verfahren zur synthese von 5- alkoxymethylfurfuralethern
ATE474845T1 (de) Verfahren zur synthese von saccharose-6-estern
ATE459416T1 (de) Verfahren zur beseitigung von endokrin wirksamen verbindungen
ATE540931T1 (de) Verfahren zur synthese organischer verbindungen
IL200320A0 (en) Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
DE602008004764D1 (de) Verfahren zur hydrokonversion von schwerölen
CY2017042I2 (el) Ενωσεις πυρρολοπυριμιδινης ως αναστολεις cdk
SMT201600267B (it) Inibitori di syk imidazopirazinici
SI2021335T1 (sl) Heterocikliäśne spojine kot zaviralci c-fms kinaze
ATE554078T1 (de) Synthese von 11-beta-hydroxysteroid-dehydrogenase-1-hemmern
ATE551342T1 (de) Heterocyclische verbindungen und zusammensetzungen als c-kit- und pdgfr- kinasehemmer
PL3354650T3 (pl) Związki przydatne jako inhibitory kinazy atr
ZA201103411B (en) Compounds useful as inhibitors of atr kinase
EP1973497A4 (de) Verfahren zur schnellen reparatur von körperleitungen
ATE543816T1 (de) Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
DK2257532T3 (da) Fremgangsmåde til regioselektiv syntese af 1-alkyl-3-haloalkyl-pyrazol-4-carboxylsyrederivater
ATE478849T1 (de) 4-anilinochinolin-3-carbonsäureamide als csf-1r- kinaseinhibitoren
EP2000567A4 (de) Verfahren zur züchtung von iii-nitrid-einzelkristallen
EP2323659A4 (de) Als proteinkinasehemmer nützliche verbindungen
DE602007008201D1 (de) Verfahren zur qualitätskontrolle von speichermedien
ATE460408T1 (de) Verfahren zur synthese von strontiumranelat und seinen hydraten
DE602006014670D1 (de) Verfahren zur doppelbindungs-hydroisomerisierung von butenen
ATE487709T1 (de) Verfahren zur synthese von 5-(methyl-1h-imidazol- 1-yl)-3-(trifluormethyl)benzolamin
DE112009001327A5 (de) Verfahren zur stereoselektiven Synthese von Phosphor-Verbindungen
DE112008002579A5 (de) Verfahren zur Synthese von A-Ring-Aromatisierten Acetyl-Minocyclinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties